Stock comparison
United Therapeutics
UTHR$24.13BHealthcare Market cap, Sector
Veracyte
VCYT$3.59BHealthcare Market cap, Sector
Overall winner
United Therapeutics
UTHR 52 VCYT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
Fit scores by strategy
UTHR5wins
2winsVCYT
71B
D50
76B
C61
76B
C65
62C
B72
46D
D50
64C
D51
64C
D56
Side-by-side metrics
| Metric | UTHR | VCYT |
|---|---|---|
| Market cap | Winner: $24.13B | $3.59B |
| P/E (TTM) | Winner: 19.2x | 34.8x |
| EV/EBIT | Winner: 15.2x | 38.4x |
| ROIC (TTM) | Winner: 18.81% | 4.73% |
| Gross margin | Winner: 86.58% | 71.31% |
| Net margin | Winner: 40.61% | 16.25% |
| Revenue CAGR 5y | 17.22% | 23.89% Winner |
| EPS CAGR 5y | 29.84% | - |
| Debt / Equity | Winner: - | 0.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
UTHR leads on
- Debt / Equity-vs 0.0x+100%
- Market cap$24.13Bvs $3.59B+85%
- ROIC (TTM)18.81%vs 4.73%+75%
- EV/EBIT15.2xvs 38.4x+60%
VCYT leads on
- Revenue CAGR 5y23.89%vs 17.22%+28%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.